Indomethacin reduces the risks of severe intraventricular hemorrhage

Henrietta S. Bada, Robert S. Green, Massroor Pourcyrous, Charles Leffler, Sheldon B. Korones, H. Lynn Magill, Kris Arheart, Charles W. Fitch, Garland D. Anderson, Grant Somes, Kay Tullis, Julia Campbell

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

A prospective, random selection, double-blind clinical trial was carried out to determine the efficacy of indomethacin in preventing periventricular-intraventricular hemorrhage (PV-IVH). Babies who were born in our institution, had birth weights ≤1500 gm, and had no PV-IVH or grade 1 PV-IVH were given either placebo (n=70) or indomethacin (n=71), 0.2 mg/kg intravenously at 6 hours of age and 0.1 mg/kg at 18 and 30 hours. Two major outcomes were determined: the development of grades 2 to 4 PV-IVH and the development of severe PV-IVH (i.e., hemorrhages with blood filling >50% of the ventricles and in some cases with associated parenchymal echodensities). Grades 2 to 4 PV-IVH occurred in 16 (23%) of the indomethacin group and 27 (39%) of the placebo group (p<0.03). The incidence of severe PV-IVH was 3% in the indomethacin-treated babies and 14% in the control group (p<0.02). The influence of other perinatal factors on the incidence of grades 2 to 4 or severe PV-IVH was determined by stepwise logistic regression. Placebo use, early grade 1 PV-IVH, lower birth weight, and higher fraction of inspired oxygen at 6 hours of life were associated with higher estimated odds of the development of grades 2 to 4 PV-IVH. Placebo use, male gender, lower 5-minute Apgar score, and a large base deficit were predictive of severe PV-IVH. Estimated odds ratios of severe PV-IVH with placebo use and male gender were 11.251 and 91, respectively. Thus indomethacin prophylaxis reduced the relative risk of grades 2 to 4 PV-IVH and severe PV-IVH, but other perinatal variables contributed significantly to the overall risk of PV-IVH.

Original languageEnglish (US)
Pages (from-to)631-637
Number of pages7
JournalThe Journal of Pediatrics
Volume115
Issue number4
DOIs
StatePublished - Jan 1 1989

Fingerprint

Indomethacin
Hemorrhage
Placebos
Birth Weight
Apgar Score
Incidence

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Cite this

Indomethacin reduces the risks of severe intraventricular hemorrhage. / Bada, Henrietta S.; Green, Robert S.; Pourcyrous, Massroor; Leffler, Charles; Korones, Sheldon B.; Magill, H. Lynn; Arheart, Kris; Fitch, Charles W.; Anderson, Garland D.; Somes, Grant; Tullis, Kay; Campbell, Julia.

In: The Journal of Pediatrics, Vol. 115, No. 4, 01.01.1989, p. 631-637.

Research output: Contribution to journalArticle

Bada, HS, Green, RS, Pourcyrous, M, Leffler, C, Korones, SB, Magill, HL, Arheart, K, Fitch, CW, Anderson, GD, Somes, G, Tullis, K & Campbell, J 1989, 'Indomethacin reduces the risks of severe intraventricular hemorrhage', The Journal of Pediatrics, vol. 115, no. 4, pp. 631-637. https://doi.org/10.1016/S0022-3476(89)80300-2
Bada, Henrietta S. ; Green, Robert S. ; Pourcyrous, Massroor ; Leffler, Charles ; Korones, Sheldon B. ; Magill, H. Lynn ; Arheart, Kris ; Fitch, Charles W. ; Anderson, Garland D. ; Somes, Grant ; Tullis, Kay ; Campbell, Julia. / Indomethacin reduces the risks of severe intraventricular hemorrhage. In: The Journal of Pediatrics. 1989 ; Vol. 115, No. 4. pp. 631-637.
@article{0a4ad08f03084783a79fabc669e14e7b,
title = "Indomethacin reduces the risks of severe intraventricular hemorrhage",
abstract = "A prospective, random selection, double-blind clinical trial was carried out to determine the efficacy of indomethacin in preventing periventricular-intraventricular hemorrhage (PV-IVH). Babies who were born in our institution, had birth weights ≤1500 gm, and had no PV-IVH or grade 1 PV-IVH were given either placebo (n=70) or indomethacin (n=71), 0.2 mg/kg intravenously at 6 hours of age and 0.1 mg/kg at 18 and 30 hours. Two major outcomes were determined: the development of grades 2 to 4 PV-IVH and the development of severe PV-IVH (i.e., hemorrhages with blood filling >50{\%} of the ventricles and in some cases with associated parenchymal echodensities). Grades 2 to 4 PV-IVH occurred in 16 (23{\%}) of the indomethacin group and 27 (39{\%}) of the placebo group (p<0.03). The incidence of severe PV-IVH was 3{\%} in the indomethacin-treated babies and 14{\%} in the control group (p<0.02). The influence of other perinatal factors on the incidence of grades 2 to 4 or severe PV-IVH was determined by stepwise logistic regression. Placebo use, early grade 1 PV-IVH, lower birth weight, and higher fraction of inspired oxygen at 6 hours of life were associated with higher estimated odds of the development of grades 2 to 4 PV-IVH. Placebo use, male gender, lower 5-minute Apgar score, and a large base deficit were predictive of severe PV-IVH. Estimated odds ratios of severe PV-IVH with placebo use and male gender were 11.251 and 91, respectively. Thus indomethacin prophylaxis reduced the relative risk of grades 2 to 4 PV-IVH and severe PV-IVH, but other perinatal variables contributed significantly to the overall risk of PV-IVH.",
author = "Bada, {Henrietta S.} and Green, {Robert S.} and Massroor Pourcyrous and Charles Leffler and Korones, {Sheldon B.} and Magill, {H. Lynn} and Kris Arheart and Fitch, {Charles W.} and Anderson, {Garland D.} and Grant Somes and Kay Tullis and Julia Campbell",
year = "1989",
month = "1",
day = "1",
doi = "10.1016/S0022-3476(89)80300-2",
language = "English (US)",
volume = "115",
pages = "631--637",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Indomethacin reduces the risks of severe intraventricular hemorrhage

AU - Bada, Henrietta S.

AU - Green, Robert S.

AU - Pourcyrous, Massroor

AU - Leffler, Charles

AU - Korones, Sheldon B.

AU - Magill, H. Lynn

AU - Arheart, Kris

AU - Fitch, Charles W.

AU - Anderson, Garland D.

AU - Somes, Grant

AU - Tullis, Kay

AU - Campbell, Julia

PY - 1989/1/1

Y1 - 1989/1/1

N2 - A prospective, random selection, double-blind clinical trial was carried out to determine the efficacy of indomethacin in preventing periventricular-intraventricular hemorrhage (PV-IVH). Babies who were born in our institution, had birth weights ≤1500 gm, and had no PV-IVH or grade 1 PV-IVH were given either placebo (n=70) or indomethacin (n=71), 0.2 mg/kg intravenously at 6 hours of age and 0.1 mg/kg at 18 and 30 hours. Two major outcomes were determined: the development of grades 2 to 4 PV-IVH and the development of severe PV-IVH (i.e., hemorrhages with blood filling >50% of the ventricles and in some cases with associated parenchymal echodensities). Grades 2 to 4 PV-IVH occurred in 16 (23%) of the indomethacin group and 27 (39%) of the placebo group (p<0.03). The incidence of severe PV-IVH was 3% in the indomethacin-treated babies and 14% in the control group (p<0.02). The influence of other perinatal factors on the incidence of grades 2 to 4 or severe PV-IVH was determined by stepwise logistic regression. Placebo use, early grade 1 PV-IVH, lower birth weight, and higher fraction of inspired oxygen at 6 hours of life were associated with higher estimated odds of the development of grades 2 to 4 PV-IVH. Placebo use, male gender, lower 5-minute Apgar score, and a large base deficit were predictive of severe PV-IVH. Estimated odds ratios of severe PV-IVH with placebo use and male gender were 11.251 and 91, respectively. Thus indomethacin prophylaxis reduced the relative risk of grades 2 to 4 PV-IVH and severe PV-IVH, but other perinatal variables contributed significantly to the overall risk of PV-IVH.

AB - A prospective, random selection, double-blind clinical trial was carried out to determine the efficacy of indomethacin in preventing periventricular-intraventricular hemorrhage (PV-IVH). Babies who were born in our institution, had birth weights ≤1500 gm, and had no PV-IVH or grade 1 PV-IVH were given either placebo (n=70) or indomethacin (n=71), 0.2 mg/kg intravenously at 6 hours of age and 0.1 mg/kg at 18 and 30 hours. Two major outcomes were determined: the development of grades 2 to 4 PV-IVH and the development of severe PV-IVH (i.e., hemorrhages with blood filling >50% of the ventricles and in some cases with associated parenchymal echodensities). Grades 2 to 4 PV-IVH occurred in 16 (23%) of the indomethacin group and 27 (39%) of the placebo group (p<0.03). The incidence of severe PV-IVH was 3% in the indomethacin-treated babies and 14% in the control group (p<0.02). The influence of other perinatal factors on the incidence of grades 2 to 4 or severe PV-IVH was determined by stepwise logistic regression. Placebo use, early grade 1 PV-IVH, lower birth weight, and higher fraction of inspired oxygen at 6 hours of life were associated with higher estimated odds of the development of grades 2 to 4 PV-IVH. Placebo use, male gender, lower 5-minute Apgar score, and a large base deficit were predictive of severe PV-IVH. Estimated odds ratios of severe PV-IVH with placebo use and male gender were 11.251 and 91, respectively. Thus indomethacin prophylaxis reduced the relative risk of grades 2 to 4 PV-IVH and severe PV-IVH, but other perinatal variables contributed significantly to the overall risk of PV-IVH.

UR - http://www.scopus.com/inward/record.url?scp=0024429299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024429299&partnerID=8YFLogxK

U2 - 10.1016/S0022-3476(89)80300-2

DO - 10.1016/S0022-3476(89)80300-2

M3 - Article

VL - 115

SP - 631

EP - 637

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 4

ER -